CTI Announces Data Presentations at the 55th American Society of Hematology Annual Meeting

 CTI Announces Data Presentations at the 55th American Society of Hematology
                                Annual Meeting

- Pacritinib Phase 2 Analysis of Myelofibrosis Patients with Thrombocytopenia
(Low Platelets) Accepted for Oral Presentation -

PR Newswire

SEATTLE, Nov. 7, 2013

SEATTLE, Nov. 7, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ
and MTA: CTIC) today announced the upcoming presentations of data highlighting
pacritinib, a novel, oral JAK2/FLT3 inhibitor, and tosedostat, an
aminopeptidase inhibitor, at the 55th American Society of Hematology (ASH)
Annual Meeting and Exposition, being held December 7-10, 2013 in New Orleans,
LA.

The presentations will include data from additional analyses of completed
Phase 2 trials of pacritinib in patients with myelofibrosis and data from
investigator-sponsored clinical trials of tosedostat for first line acute
myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and a separate study
in relapsed patients. A summary of the presentations is below, and full
abstracts can be accessed on the ASH website at www.hematology.org.

Oral Presentation

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety
Analysis of Phase II Trial Data in Patients with Primary and Secondary
Myelofibrosis (MF) and Platelet Counts ≤ 100,000 µL

  oFirst Author: Dr. Srdan Verstovsek, MD Anderson Cancer Center, Houston,
    TX
  oDate/Time: Monday, December 9, 2013 at 11:30 a.m. CT
  oLocation: Theater C
  oOral Session: 634, Myeloproliferative Syndromes: Clinical I
  oAbstract #395

Poster Presentations

A Phase I/II Study of Cytarabine or Azacitidine in Combination with Tosedostat
in Older Patients with AML or High-Risk MDS

  oFirst Author: Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, TX
  oDate/Time: Sunday, December 8, 2013, 6:30-8:30 p.m. CT
  oLocation: Hall E
  oPoster Presentation: 615, Acute Myeloid Leukemia: Therapy, excluding
    Transplantation: Poster II
  oAbstract #2698

A Phase II Study of Tosedostat (TST) in Combination with Either Cytarabine or
Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML)
or High-Risk Myelodysplastic Syndrome (MDS)

  oFirst Author: Dr. Raya Mawad, Fred Hutchinson Cancer Research Center,
    University of Washington, Seattle, WA
  oDate/Time: Monday, December 9, 2013, 6:00-8:00 p.m. CT
  oLocation: Hall E
  oPoster Presentation: 615, Acute Myeloid Leukemia: Therapy, excluding
    Transplantation: Poster III
  oAbstract #3926

Exposure-Response Analysis for Pacritinib (SB1518), a Novel Oral JAK2/FLT3
Inhibitor, In Patients With Myelofibrosis

  oFirst Author: Dr. Suliman Al-Fayoumi, Cell Therapeutics, Inc., Seattle,
    WA
  oDate/Time: Monday, December 9, 2013 at 6:00-8:00 p.m. CT
  oLocation: Hall E
  oPoster Presentation: 634, Myeloproliferative Syndromes: Clinical: Poster
    III
  oAbstract #4080

About Pacritinib

Pacritinib is an oral tyrosine kinase inhibitor (TKI) with dual activity
against JAK2 and FLT3. The JAK family of enzymes are a central component in
signal transduction pathways, which are critical to normal blood cell growth
and development as well as inflammatory cytokine expression and immune
responses. Mutations in these kinases have been shown to be directly related
to the development of a variety of blood related cancers including
myeloproliferative neoplasms, leukemia and lymphoma. Pacritinib may offer an
advantage over other JAK inhibitors through effective treatment of symptoms
while having less treatment-emergent thrombocytopenia and anemia than has been
seen in currently approved and in-development JAK inhibitors.

CTI is pursuing a broad approach to advancing pacritinib for patients with
myelofibrosis by conducting two Phase 3 clinical trials: one in a broad set
of patients without limitations on blood platelet counts, the PERSIST-1 trial,
and the other will be in patients with low platelet counts, the PERSIST-2
trial, which is expected to begin in the fourth quarter of 2013. In October
2013, we reached agreement with the U.S. Food and Drug Administration on a
Special Protocol Assessment, or SPA, for the PERSIST-2 pivotal trial. A SPA
is a written agreement between CTI and the FDA regarding the design, endpoints
and planned statistical analysis approach of the trial to be used in support
of a potential New Drug Application, or NDA, submission. 

About Tosedostat

Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated
significant anti-tumor responses in blood-related cancers and solid tumors in
Phase 1-2 clinical trials. CTI has exclusive marketing and co-development
rights to Chroma Therapeutics Ltd.'s drug candidate tosedostat in North,
Central and South America.

About Cell Therapeutics, Inc.

CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the
development and commercialization of an integrated portfolio of oncology
products aimed at making cancer more treatable. CTI is headquartered in
Seattle, WA. For additional information and to sign up for email alerts and
get RSS feeds, please visit www.CellTherapeutics.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Safe Harbor provisions of the Private Securities Litigation Reform Act of
1995. Such statements are subject to a number of risks and uncertainties, the
outcome of which could materially and/or adversely affect actual future
results and the trading price of CTI's securities. Such statements include,
but are not limited to, statements regarding CTI's expectations with respect
to the development of CTI and its product and product candidate portfolio, the
expected commencement of the PERSIST-2 clinical trial in the fourth quarter of
2013 and the expected efficacy and potential benefits of pacritinib (including
that pacritinib may offer an advantage over other JAK inhibitors through
effective treatment of symptoms while having less treatment-emergent
thrombocytopenia and anemia than has been seen in currently approved and
in-development JAK inhibitors). Risks that contribute to the uncertain nature
of the forward-looking statements include, among others, risks associated with
the biopharmaceutical industry in general and with CTI and its product and
product candidate portfolio in particular including, among others, risks
associated with the following: that CTI cannot predict or guarantee the pace
or geography of enrollment of its clinical trials, that CTI cannot predict or
guarantee the outcome of preclinical and clinical studies, that the second
Phase 3 clinical trial of pacritinib will not occur as planned, that CTI may
not obtain favorable determinations by other regulatory, patent and
administrative governmental authorities, that CTI may experience delays in the
commencement of preclinical and clinical studies, risks related to the costs
of developing pacritinib and CTI's other product candidates, and other risks,
including, without limitation, competitive factors, technological
developments, that CTI's operating expenses continue to exceed its net
revenues, that CTI may not be able to sustain its current cost controls or
further reduce its operating expenses, that CTI may not achieve previously
announced goals and objectives as or when projected, that CTI's average net
operating burn rate may increase, that CTI will continue to need to raise
capital to fund its operating expenses, but may not be able to raise
sufficient amounts to fund its continued operation as well as other risks
listed or described from time to time in CTI's most recent filings with the
Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as
required by law, CTI does not intend to update any of the statements in this
press release upon further developments.



Contacts:
Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com 

Ed Bell
+1 206-282-7100
ebell@ctiseattle.com 

In Europe:

CTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 89659706
lvilla@cti-lifesciences.com
CTI_EUInvestors@CTI-Lifesciences.com

SOURCE Cell Therapeutics, Inc.

Website: http://www.celltherapeutics.com